Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
Here, the authors report results from a Phase 1 trial with an AS03-adjuvanted, plant-based virus-like particle displaying the spike protein of the ancestral SARS-CoV-2. Six months post-second dose, they observe good neutralizing antibody titers and T cell responses to ancestral virus and variants of...
Main Authors: | Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Nathalie Charland, Aurélien Lorin, Matthew P. Cheng, Donald C. Vinh, Philippe Boutet, Robbert Van Der Most, François Roman, Maria Angeles Ceregido, Nathalie Landry, Marc-André D’Aoust, Brian J. Ward |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-34728-1 |
Similar Items
-
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
by: Nathalie Charland, et al.
Published: (2022-11-01) -
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
by: Brian J. Ward, et al.
Published: (2018-03-01) -
Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity
by: Hilary E. Hendin, et al.
Published: (2022-04-01) -
Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
by: Paulina Kaplonek, et al.
Published: (2023-02-01) -
Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
by: Breanna Hodgins, et al.
Published: (2019-11-01)